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Available online 26 June 2016In developing countries, clarithromycin resistance and frequency of re-infection are factors that contribute to
high prevalence of Helicobacter pylori infection. The aim of this research was determine the prevalence of
clarithromycin resistance and its relation with A2142G, A2142C and A2143G mutations in the domain V of the
23S rRNA gene of H. pylori isolates in patients from Southern Mexico with chronic gastritis. Another purpose of
this work was to study the prevalence of virulent genotypes and distribution of resistant strains according to
the vacA/cagA/babA2 H. pylori genotypes. One hundred forty-four patients with chronic gastritis were studied.
Forty-ﬁve H. pylori strains were isolated and clarithromycin susceptibility was determined by the disk-
diffusion method. The 82.2% of the strains had the combination of alleles vacA s1m1 and the cagA gene was de-
tected in 77.8% and 40% of the strainswere babA2 positive. The vacA s1m1 genotypewas detectedmore frequent-
ly in cagA+ strains, vacA s1m1/cagA+/babA2- genotype wasmore frequent than vacA s1m1/cagA+/babA2+, 37.8%
and 33.3%, respectively. Eight strains were clarithromycin resistant, in three of these, point mutations were iden-
tiﬁed, but only in one strain the A2143G mutation associated with clarithromycin resistance was found. Other
point mutations (A1821G, G1826A, T1830C, A2089G, T1600C, C1601T, C1602T, T1610C, A1611C and T1633G)
that have not been associated with clarithromycin resistance were identiﬁed. The highest proportion of resistant
strains was vacA s1m1/cagA+ (62.5%). In patients from southern Mexico with chronic gastritis, the prevalence of
clarithromycin resistance is within internationally accepted range (17.8%) and allows continued use of triple
therapy for H. pylori eradication. However, it is necessary to monitor the evolution of clarithromycin resistance
in this area. The largest proportion of resistant H. pylori strains is not harboring the A2142G, A2142C and
A2143G mutations in the 23S rRNA gene (87.5%). The vacA s1m1/cagA+ genotype was the most prevalent and
among clarithromycin-resistant strains, this was the predominant.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Persistent Helicobacter pylori infection causes chronic gastritis, gas-
tric or duodenal ulcers and gastric cancer. Virulence factors like CagA
and VacA cytotoxins and BabA2 adhesin, characteristic of H. pylori viru-
lent strains, are determinants of tissue damage and are associated with
the clinical diagnosis (Broutet et al., 2003). In 50% to 60% of the strains
isolated in Western countries are cagA-positive. In Mexico, the preva-
lence of H. pylori cagA-positive, determined by anti-CagA antibodies or
by ampliﬁcation of cagA varies between 40% and 90% in patients with
gastric disease in different parts of the country (Bosques-Padilla et al.,
2003; Camorlinga-Ponce et al., 2008; López-Carrillo et al., 2004;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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genic protein that causes severe inﬂammation through induction of IL-
1β, IL-8 and TNF-α. Both, IL-1β and TNF-α, are potent inhibitors of the
secretion of hydrochloric acid and high levels of these cytokines favor
an increase in gastric pH (Beales and Calam, 1998; Brandt et al., 2005).
It is likely that IL-1β and TNF-α levels are associated with eradication
rates ofH. pylori infection (Sugimoto and Yamaoka, 2009). VacA is asso-
ciated with gastric cancer and with incidence of severe gastric diseases.
vacA is a gene with variable structure in the signal region (s), s1 or s2;
the intermediate region (i) existing as subtypes 1 and 2, and themiddle
region (m)withm1 andm2 allelotypes (Gangwer et al., 2010; Rudi et al.,
1998). The s1m1 and s1m2 genotypes generate isoforms of VacA that di-
rectly damage the gastric epithelium and induce an acute inﬂammatory
process, which may progress to chronic gastritis or gastric ulcers
(Atherton et al., 1995; Blaser and Atherton, 2004; Caricio et al., 2005;
Chang et al., 2006; Marciorkowska et al., 2007). The risk of gastric dis-
ease is greater in infected patients with strains expressing CagA and
BabA2 (Muhammad et al., 2013; Roesler et al., 2014). BabA2 adhesin
binds Lewis antigens in gastric epithelium, favoring persistence of
H. pylori and translocation of CagA to the epithelial cell (Delahay and
Rugge, 2012).
It has been reported that clarithromycin susceptibility varies among
genotypes of H. pylori, and that vacA s2m2/cagA-negative strains are
more resistant to that antibiotic than vacA s1m2 and vacA s1m1/cagA-
positive strains (Agudo et al., 2010; Van Doorn et al., 2000). Patients in-
fected with H. pylori vacA s1m1/cagA -positive strains have high cure
rates because the inﬂammation caused by these genotypes increases
blood ﬂow and therefore the diffusion of antibiotics (Sugimoto and
Yamaoka, 2009).
Because of the causal relationship between H. pylori with gastric
neoplasms, eradication therapy is recommended in all symptomatic pa-
tients (Smith et al., 2014). The IVMaastricht consensus recommend, as a
ﬁrst option for the management of H. pylori infection, therapy with a
proton pump inhibitor (PPI), and a combination of two antibiotics,
clarithromycin and amoxicillin or metronidazole for 10 to 14 days. It is
recommended to include clarithromycin in regions where resistance
to this antibiotic is b20% (Abdo et al., 2007; Malfertheiner et al.,
2012). Clarithromycin acts by binding to the peptidyltransferase region
of the 23S rRNA, inhibiting bacterial protein synthesis (De Francesco
et al., 2011; Ierardi et al., 2013). Clarithromycin is the key antibiotic
for the eradication ofH. pylori, because it is better absorbed in the gastric
mucosa, ismore stable at lower pHand thereforemore effective (Cobos-
Trigueros et al., 2009). The emergence of strains resistant to this antibi-
otic decreases eradication rates. The prevalence of clarithromycin resis-
tance in H. pylori varies for each area; in America it is 29.3%, 11.1% in
Europe, 18.9% in Asia and 92.3% in Africa (Papastergiou et al., 2014;
Wu et al., 2012). InMexico, the frequency of resistance to this antibiotic
ranges from 4% to 25% and changes with the geographic area (Ayala
et al., 2011; Chihu et al., 2005; Garza-González et al., 2002;
Morales-Espinosa et al., 2007; Torres et al., 2001). Point mutations in
the coding region peptidyltransferase in the domain V of the 23S rRNA
gene of H. pylori are responsible for clarithromycin resistance, by mod-
ifying the target site. These mutations occur at random, favored by the
presence of the antibiotic on the microenvironment. Mutant strains ex-
ceed the growth of the parent strain, replace them and persist. Point
mutations in the 23S rRNA gene positions T2182C, T2190C, C2195T,
C2611A and A2223G (Chihu et al., 2005; De Francesco et al., 2011;
Kim et al., 2008) have been associated with clarithromycin resistance,
but the highest proportion of resistant cases are associated with muta-
tions A2142G, A2142C and A2143G (Agudo et al., 2010; Kargar et al.,
2012; Llanes et al., 2010; Suzuki et al., 2013; Trespalacios et al., 2013).
Strains with A2142G, A2142C and A2143G mutations tolerate a higher
concentration of the antibiotic. In other bacterial species, production
of the antibiotic inactivating enzymes (esterase, glicosylase and phos-
photransferase), production of enzymes modifying target site (methyl-
ases) or the presence of efﬂux pumps are resistance mechanisms tomacrolids (Cobos-Trigueros et al., 2009). In H. pylori, the presence of
genes that encode proteins of the efﬂux pump was conﬁrmed (Bina
et al., 2000). The removal of the antibiotic to the exterior of the bacteri-
um through of efﬂux pump prevents the antibiotic from binding to the
ribosome (Wu et al., 2012). The treatment failure lead to the persistence
of H. pylori and increases the risk of severe gastric diseases (Smith et al.,
2014). In Mexico, amoxicillin and clarithromycin are widely used for
H. pylori eradication in some geographical regions and 80% effectiveness
is achieved (Abdo et al., 2007; Malfertheiner et al., 2012). However, the
widespread establishment of this therapy is not based in the knowledge
about the prevalence of resistance to these antibiotics. There are few
studies on the prevalence of clarithromycin resistance carried out in
Mexican population; they have covered a limited geographical area
and none in population of the south region (Ayala et al., 2011; Chihu
et al., 2005; Garza-González et al., 2002; Morales-Espinosa et al., 2007;
Torres et al., 2001). Knowledge of clarithromycin susceptibility in
H. pylori locally, is useful for selecting appropriate treatment.
The aim of this research was determine the prevalence of
clarithromycin resistance and its relation with A2142G, A2142C and
A2143Gmutations in the domain V of the 23S rRNAgene ofH. pylori iso-
lates in patients from Southern Mexico with chronic gastritis. Another
purpose of this work was to study the prevalence of virulent genotypes
and distribution of resistant strains according to the vacA/cagA/babA2 H.
pylori genotypes.2. Materials and methods
2.1. Patients
A cross-sectional study was conducted in 144 patients recruited from
the Gastroenterology Service of the General Hospital “Dr. Raymundo
Abarca Alarcón” and the Specialized Unit of Gastroenterology Endoscopy,
in Chilpancingo, Guerrero State, Mexico. Patients were sequentially
selected among thosewhounderwent endoscopybecause they suffered
from dyspepsia symptoms. Patients in this study had not received
antibiotic treatment for H. pylori eradication, proton pump inhibitors
or gastric pH-neutralizing agents during the 15 days prior to the endo-
scopic procedure. Patients who received non-steroid anti-inﬂammatory
treatment were excluded from the study. The study participants signed
a letter of informed consent. This project was approved by the Bioethics
Committee of the Autonomous University of Guerrero and participating
hospitals.2.2. Biopsy collection
After an overnight fast, the endoscopic study was performed with
a video processor and a video gastroscope (Fujinon, Wayne, NJ USA).
Three antral biopses from each patient were collected. The ﬁrst biop-
sy was deposited in Brain Heart Infusion (BHI) (Becton Dickinson,
North Carolina, USA) with 10% glycerol for bacteriological culture.
A second biopsy was ﬁxed immediately in 10% formalin for histolog-
ical analysis, another was placed in a buffered solution (10 mM Tris,
pH 8, 10 mM EDTA, 0.5% SDS) for DNA extraction. Biopsies were
transported at 4 °C and those for the isolation of H. pylori, were proc-
essed immediately.2.3. Histology
The formalinﬁxed biopseswere embedded in parafﬁn, and4 μmsec-
tionswere stainedwith hematoxylin-eosin for histological analysis. His-
topathological ﬁndings were used to determine the diagnosis of each
patient. Gastritis was classiﬁed according to the updated Sydney system
(Dixon et al., 1997).
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Each biopsy transported in BHI broth with 10% glycerol was macer-
ated using a sterile wooden applicator. Fifty microliters of homogenate
was placed in a Columbia agar plate (Becton Dickinson, North Caroline,
USA) supplemented with 10% sheep blood, Isovitalex enrichment
(Becton Dickinson, North Caroline, USA) and Dent antibiotic selective
supplement (Oxoid, Basingstoke, United Kingdom) at pH 6.8 to 7.0. Ho-
mogenate was distributed in the culture medium. Inoculated plates
were incubated under microaerophilic conditions with 2% to 5% O2
levels, 5% to 10% CO2 at 37 °C in GasPak jars for 3 days. H. pylori was
identiﬁed by colony morphology (small colonies, transparent, 1 mm in
diameter), Gram staining and biochemical tests (urease, catalase and
oxidase positive). As a positive control, H. pylori strain ATCC 43504
was used. The isolates were stored at -70 °C in 1.5 mL Brain Heart Infu-
sion Broth (Becton Dickinson, North Caroline, USA) with 30% glycerol,
until they were used.
2.5. DNA extraction
From the isolates identiﬁed as H. pylori, subcultures incubated for
72 h were performed. A pool of colonies from each biopsy was placed
in a buffered solution (10mMTris, pH 8, 10mMEDTA, 0.5% SDS) for di-
gestion with Proteinase K. Total DNA was extracted by phenol-
chloroform-isoamyl alcohol technique (Sambrook and Russel, 2001).
Total DNA concentration was determined in the NanoDrop 2000
(NanoDrop Technologies, Wilmington, DE). Biopsies maintained in
buffered solution used as a source of genomic DNA, whichwas obtained
by the procedures used for bacterial DNA. The DNA strains and biopsies
were stored at -20 °C until use.
2.6. Molecular conﬁrmation and genotyping of vacA, cagA and babA2 of
H. pylori
Conﬁrmation of H. pyloriwas performed using the primers HP16SF
andHPGR16SR that amplify a 522 bp fragment of the 16S rRNAgene, ac-
cording to the method described by Román-Román et al., (Román-
Román et al., 2013). Genotyping of vacA, cagA and babA2 status by mul-
tiplex PCR was performed with speciﬁc primers for each region and
gene listed in Table 1. The reaction mixture consisted of 1.5 mM
MgCl2, 0.2 mM dNTP's, 2.5 pmol of F1 and B1 primer; 5 pmol of VAGF
and VAGR; 2.5 pmol of VAIF and VAIR; 12.5 pmol of babA2F and
babA2R, 1.5 U of Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA)
and 200 ng of DNA in a total volume of 25 μL. The ampliﬁcationTable 1
Primers used in this study.
Primers/probes
Primer sequence
(5′ to 3′) Target
HP16S F GCTAAGAGATCAGCCTATGTCC 16S
rRNAHPGR16S R CAATCAGCGTCAGTAATGTTC
Hp23S F TCAGTGAAATTGTAGTGGAGGTGAAAA 23S
rRNAHp23S R CAGTGCTAAGTTGTAGTAAAGGTCCA
CLA23S F GGACGCATAGGGTTAAGC 23S
rRNAK2R CTCCATAAGAGCCAAAGCCC
cagA F1 GATAACAGGCAAGCTTTTGAGG cagA
cagA B1 CTGCAAAAGATTGTTTGGCAGA
VAG F CAATCTGTCCAATCAAGCGAG vacA
m1/m2VAG R GCGTCTAAATAATTCCAAGG
VA1 F ATGGAAATACAACAAACACAC vacA
s1/s2VA1 R CTGCTTGAATGCGCCAAAC
babA2 F AATCCAAAAAGGAAAAACATGAAA babA2
babA2 R TGTTAGTGATTTCGGTGTAGGACA
PWT VIC-AAGACGGAAAGACC-MGBNFQ Wild type
P2142G FAM-AAGACGGGAAGACC-MGBNFQ A2142G
P2142C FAM-CAAGACGGACAGACC-MGBNFQ A2142C
P2143G FAM-CAAGACGGAGAGACC-MGBNFQ A2143Gconditions were 1 cycle at 94 °C for 10 min, 35 cycles at 94 °C for
1 min; 57 °C for 1 min; 72 °C for 1 min and a ﬁnal extension cycle at
72 °C for 10 min. The PCR products were subjected to electrophoresis
on a 1.5% agarose gel, followed by ethidium bromide staining and visu-
alized under ultraviolet (UV) light. In all reactionsDNAofH. pylori strain
ATCC 43504 was used as positive control, and for a negative control,
DNA was substituted with sterile deionized water. All PCRs were per-
formed in a gradient thermocycler (Eppendorf Mastercycler ep gradi-
ent, Germany).
2.7. Susceptibility testing
Clarithromycin susceptibility was determined by disk-diffusion
(Kirby Bauer) method (Grignon et al., 2002; Henao et al., 2009;
Mishra et al., 2006). Fresh H. pylori isolates from 72 h subculture on
Columbia agar were diluted in sterile BHI broth and adjusted to a 3.0
McFarland standard (≥108 cfu/mL viable cells) (Boyanova et al., 2000;
Grignon et al., 2002; Mishra et al., 2006). The bacterial suspension was
spread on Petri plates (90mmdiameter) containing Columbia agar sup-
plementedwith 10% sheep blood and Isovitalex enrichment at pH 6.8 to
7.0. The inoculum was dispersed with a sterile swab in four directions,
to completely cover the surface of the medium. Discs with 2 μg, 5 μg
and 15 μg of clarithromycin (Oxoid, Basingstoke, United Kingdom)
were placed on a dry surface of the plate. The plates were incubated
under microaerophilic conditions (5% O2, 10% CO2) at 37 °C for 72 h.
The H. pylori strain ATCC 43504, clarithromycin susceptible, was used
as control to determine breakpoints (Grignon et al., 2002; Henao et al.,
2009; Mishra et al., 2006). H. pylori strains were considered resistant
to 2 μg of clarithromycin if their inhibition zone was ≤18 mm, 5 μg
when was ≤23 mm and 15 μg when was observed ≤28 mm
(Boyanova et al., 2000; McNulty et al., 2002; Mohammadi et al., 2005).
Susceptibility tests were performed in duplicate in all isolates.
2.8. Molecular detection of clarithromycin resistance
To detect pointmutations associatedwith clarithromycin resistance,
PCR-RFLPwas performed. A fragment of 87 bp of the 23S rRNAgenewas
ampliﬁed using the Hp23SF (2091–2117) and Hp23SR (2177–2152)
primers of Table 1. The reaction mixture consisted of 2 mM MgCl2,
0.4 mM dNTP's, 5 pmol of each primer, 1 U of Taq DNA polymerase
(Jena Bioscience, Frankfurt, Germany) and 100 ng of DNA in a total vol-
ume of 25 μL. The ampliﬁcation conditions were 1 cycle at 95 °C for
5 min; 45 cycles at 95 °C for 30 s; 58 °C for 30 s and a ﬁnal extension
cycle at 72 °C for 30 s. The amplicons were subjected to electrophoresisAnnealing temperature Size (bp) Reference
55 °C 522 Román-Román et al. (2013)
Román-Román et al. (2013)
58 °C 87 De Francesco et al. (2006)
De Francesco et al. (2006)
58 °C 715
Kim et al. (2002)
57 °C 349 Park et al. (2001)
Park et al. (2001)
57 °C 570/645 Atherton et al. (1999)
Atherton et al. (1999)
57 °C 259/286 Atherton et al. (1995)
Atherton et al. (1995)
57 °C 850 Mizushima et al. (2001)
Mizushima et al. (2001)
De Francesco et al. (2009)
De Francesco et al. (2009)
De Francesco et al. (2009)
De Francesco et al. (2009)
Fig. 1. Detection of the A2143G mutation in the 23S rRNA gene of H. pylori by digestion
with BsaI enzyme. The PCR products were analyzed on a 3.5% agarose gel stained with
ethidium bromide. Lane 1: molecular weight marker (20 bp); lanes 2 and 3: susceptible
strain; lane 4: H. pylori control strain ATCC 43504; lane 5: negative control; lane 6:
UEGE 856 strain with A2143G mutation.
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under ultraviolet (UV) light. PCR products were digested by the restric-
tion enzymes, BbsI ([GAAGAC] 59 and 28 bp) for the A2142G mutation,
BceAI ([ACGGC] 64 and 23 bp) for the A2142Cmutation and BsaI for the
A2143G mutation ([GGTCTC] 40 and 47 bp) (BioLabs Inc., New En-
gland), (Fig. 1). To reﬁne the search of point mutations in the 23S
rRNA gene, qPCR (real time PCR) was performed using primers men-
tioned previously and hydrolysis probes (De Francesco et al., 2009)
listed in Table 1. All samples were tested in duplicate. Positive and
negative controls were included. The qPCR was performed in StepOne
(Applied Biosystems, Foster City, CA, USA) and data were analyzed
with the StepOne software version 2.3. Additionally, a 715 bp fragment
of the 23S rRNA gene (GenBank accession number U27270) was
ampliﬁed using the CLA23SF (1526–1544) and K2R (2242–2223)
primers as indicated in Table 1. The reaction mixture consisted of
2 mM MgCl2, 0.4 mM dNTP's, 5 pmol of each primer, 1 U of Taq DNA
polymerase (Jena Bioscience, Frankfurt, Germany) and 100 ng of total
DNA in a total volume of 25 μL. The ampliﬁcation conditions were
1 cycle at 95 °C for 5 min; 45 cycles at 95 °C for 30 s; 58 °C for 30 s
and a ﬁnal extension cycle at 72 °C for 30 s. The ampliﬁcation products
were subjected to electrophoresis on a 1.5% agarose gel, stained with
ethidium bromide and observed under ultraviolet light (UV). The PCR
products from eight resistant isolates were puriﬁed with PureLink
PCR Puriﬁcation Kit (Invitrogen, Carlsbad, CA, USA) following the
manufacturer's instructions. The puriﬁed fragments were sequenced
with the BigDye Terminator v 1.1 sequencing kit (Applied Biosystems,
Foster City, CA, USA) and analyzed with ABI PRISM 310 Genetic Analyzer
(Applied Biosystems). The obtained sequences were aligned with
H. pylori strain 26695 (Fig. 2), using the sequence analysis program
ClustalW1.83 (European Bioinformatics Institute), (Chenna et al., 2003).
2.9. Statistical analysis
The data were processed with the statistical program STATA version
11. Mean and standard deviation of parametric quantitative variables
were determined. The correlation between culture and PCR for
H. pylori was calculated using the kappa index. We apply X2 or Fisher's
exact test to compare frequencies between groups. A p-value b0.05
was considered statistically signiﬁcant.
3. Results
3.1. Population characteristics and H. pylori infection
A total of 144 gastric biopsies were obtained from patients with his-
topathological diagnosis of chronic gastritis. Of all H. pylori-positivepatients, 57.8% (26/45) had active chronic gastritis, 40% (18/45) had fol-
licular gastritis and only one (2.2%) had atrophic gastritis. Active
H. pylori infection was found in 31.3% (45/144) of patients. The mean
age of patients was 48.3 ± 16.7 (range 19–87 years). The participation
of female patients was higher (68%) than that of the male gender
(p= 0. 052), (Table 2).
The prevalence of H. pylori infection detected by culture was very
similar to that obtained by conventional PCR; however, there were dif-
ferences in frequencies (p b 0.001). Good agreement was found be-
tween the results of culture and PCR (κ= 0.731) (Table 3). All strains
identiﬁed as H. pylori in culture (45/45) were conﬁrmed by PCR, ampli-
fying a fragment of the 16S rRNA gene.
3.2. Clarithromycin susceptibility
Using the disk-diffusion method, forty-ﬁve H. pylori isolates were
tested for their clarithromycin susceptibility. The percentage of
clarithromycin resistant isolates was 17.8% (8/45) in 2 μg, 5 μg and
15 μg. The 82.2% (37/45) of isolateswere clarithromycin susceptible. Pa-
tients harboring resistant strains, 62.5% (5/8) reported consumption of
proton-pump inhibitors as previous treatment, and 75% (6/8) of resis-
tant strains were isolated from female patients.
3.2.1. Concordance between phenotypic and genotypic clarithromycin
resistance
The DNA of 45 isolates were subjected to PCR-RFLPs to ﬁnd themost
frequentmutations associatedwith clarithromycin resistance in the 23S
rRNA gene. Only the amplicon of UEGE 856 isolate was completely
digested by BsaI, which detected A2143G mutation. This isolate was
one of eight clarithromycin resistant by the disk-diffusion method
(Kirby Bauer). In any isolate was observed partial digestion (Fig. 1).
The 12.5% (1/8) of phenotypically clarithromycin resistant isolates
showed A2143G mutation (UEGE 856). In clarithromycin susceptible
isolates (37/45), mutations commonly associated with resistance were
not detected (Fig. 1). These results were corroborated using hydrolysis
probes. Sequencing of a 715 bp fragment of the 23S rRNA gene of
eight phenotypically clarithromycin resistant isolates conﬁrmed the
A2143G mutation in UEGE 856 strain and additional mutations in
other positions (A1821G, G1826A, T1830C, A2089G). Three mutations
in the same positions as the UEGE 856 were found in the HG 162 strain
(A1821G, G1826A, T1830C), and six mutations (T1600C, C1601T,
C1602T, T1610C, A1611C, T1633G) in the HG 193 strain, which are dif-
ferent from those found in UEGE 856 and HG 162 strain (Fig. 2). The
H. pylori strainwith the A2143Gmutation (UEGE 856) has the combina-
tion vacA s2m2/cagA-/babA2- while theHG 162 andHG193 lack themu-
tations related with clarithromycin resistance and harboring the vacA
s1m1/cagA+/babA2+ genotype. The percentage of clarithromycin resis-
tant strains determined by phenotypic method (17.8% [8/45]) was
higher than the percentage of isolates relatedwithmutations associated
to clarithromycin resistance (2.2% [1/45]). Mutations in the 23S rRNA
gene commonly associated with clarithromycin resistance were not
found in seven of eight clarithromycin resistant strains by disk-
diffusion method. Detection of mutations from each colony was not
made.
3.2.2. Clarithromycin resistance and vacA genotype, cagA and babA2 status
In order to verify the vacA genotype, cagA and babA2 status in
H. pylori, all isolates were genotyped by multiplex PCR. The cagA gene
was detected in 77.8% (35/45) of the strains. The vacA allelic variants
were determined in 100% of strains (45). The s1 allele was found in
84.5% (38/45) of the strains and the combination of alleles of vacA
s1m1 in 80% (36/45); 15.5% (7/45) of the strains had the vacA s1m2 ge-
notype and 2.2% (1/45) the s1m2 and s1m1/s1m2 combination; babA2
was detected in 40% (18/45) of the strains. The vacA s1m1 mosaicism
was found in combination with cagA+, 73.3% (33/45) of the strains,
and vacA s1m1/cagA+/babA2- genotype was more frequently found
Fig. 2. Sequence alignment of the 23S rRNA gene ofH. pylori strains. The base sequence of the 23S rRNA gene fragment of three strains isolated from patients with chronic gastritis aligned
with the base sequence of the reference H. pylori strain 26695. Six point mutations were found in HG 193 strain (T1600C, C1601T, C1602T, T1610C, A1611C, T1633G); ﬁve in UEGE 856
strain (A1821G, G1826A, T1830C, A2089G, A2143G), and three in HG 162 strain (A1821G, G1826A, T1830C), compared to the control strain 26695. Unreportedmutations in other studies
are shown in yellow. The A2143G mutation is shown in green.
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spectively. Therewere no signiﬁcant differences among the distribution
of each combination of genotypes between clarithromycin resistant and
susceptible strains. In detail, 20% (3/15) of strains with genotype vacAs1m1/cagA+/babA2+ were clarithromycin resistant and 11.8% (2/17)
of all vacA s1m1/cagA+/babA2- were resistant too. Interestingly, 33.3%
(2/6) of the vacA s2m2/cagA-/babA2- strains were clarithromycin resis-
tant (Table 5). The percentage of clarithromycin resistant isolates that
Table 2
Characteristics of patients with chronic gastritis.
Chronic Gastritis
H. pylori-positive
n= 45
H. pylori-negative
n= 99
p value
Age (mean ± SD; years) 46.1 ± 19.5 49.2 ± 15.3 0.403a
Gender n (%)
Female 22 (48.9) 67 (67.7) 0.052b
Male 23 (51.1) 32 (32.3)
Previous treatment n (%)
PPI⁎ 20 (44.4) 30 (30.3) 0.295c
Clarithromycin 0 2 (2.0)
⁎ Proton Pump Inhibitor.
a Student t-test.
b X2 test.
c Fisher's exact test.
Table 4
Distribution of vacA genotypes, cagA and babA2 status inH. pylori strains isolated from pa-
tients with chronic gastritis.
Genes
Clarithromycin
n= 45
p value
Susceptible
n= 37
Resistant
n= 8
cagA n (%)
Positive 30 (81.1) 5 (62.5) 0.349⁎
Negative 7 (18.9) 3 (37.5)
vacA n (%)
s1m1 30 (81.1) 6 (75) 0.729⁎
s2m2 5 (13.5) 2 (25)
s1m2 1 (2.7) 0
s1m1/s1m2 1 (2.7) 0
babA2 n (%)
Positive 14 (37.8) 4 (50) 0.452⁎
Negative 23 (62.2) 4 (50)
⁎ Fisher's exact test.
Table 5
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(2/6) had vacA s2m2/cagA-. There were not signiﬁcant differences in ge-
notype distribution and clarithromycin resistance or susceptibility
(p N 0.05) (Tables 4 and 5).
4. Discussion
It has been reported that the frequency of H. pylori infection varies
between geographical areas. In the present studywe found a prevalence
of H. pylori of 32.6% (47/144) and a frequency isolation of H. pylori in
31.3% (45/144), higher than reported in 2005 by Chihu et al., (26.1%),
but lower than reported by Paniagua et al., 2009, who obtained 60.1%
of isolates of H. pylori in patients with chronic gastritis. The differences
in the frequency of isolates may be due to the uneven distribution of
bacteria in the affected area, the number of viable bacteria in the biopsy,
to differences in the culture conditions used in each study and the geo-
graphic area of origin the patients. Although the patients included in
this study reported not having been treated to eradicate H. pylori infec-
tion, it is impossible to ensure the absence of information bias and
memory bias.
Currently, a combination of two tests to diagnose H. pylori infection
is recommended, because of their uneven distribution in the stomach
(Malfertheiner et al., 2012). In this research the prevalence of H. pylori
detected by culture, 31.2% (45/144) was similar to that found by PCR,
32.6% (47/144). There was good agreement between both methods to
detect H. pylori infection (κ= 0.731). Discrepancies can be explained
by the difference in sensitivity and speciﬁcity of each method (sensitiv-
ity of 80%–98% and speciﬁcity of 100% for culture; sensitivity of 75%–
100% and speciﬁcity of 84%–100% for PCR) (Abdo et al., 2007; Patel
et al., 2014), the site of obtaining the biopsy processed by each method
and the bacterial load present in each biopsy. Thus, the PCR and the cul-
ture are complementary methods in H. pylori detection.
In developing countries, re-infection and clarithromycin resistance
are factors that contribute to the failure of H. pylori eradication.
Clarithromycin is included in the standard triple therapy. To our knowl-
edge, only ﬁve studies report the prevalence of clarithromycinTable 3
Concordance between H. pylori detection by culture and PCR in patients with chronic
gastritis.
Culture
PCR
Positive
n (%)
Negative
n (%)
Total
n (%)
Positive 37 (78.7) 8 (8.2) 45 (31.3)
Negative 10 (21.3) 89 (91.8) 99 (68.7)
Total 47 (100) 97 (100) 144 (100)
Kappa = 0.731.resistance in Mexican population (Ayala et al., 2011; Chihu et al.,
2005; Garza-González et al., 2002; Morales-Espinosa et al., 2007; Torres
et al., 2001) and in four of them, patients fromMexico citywere studied.
The frequency of phenotypic clarithromycin resistance in H. pylori
strains isolated from patients with chronic gastritis from the Guerrero
State was 17.8% (8/45). This result is lower than that reported in 2001
by Torres et al., (24%) and higher than reported in other studies in the
Mexican population where the frequency of resistance varies between
4% and 8% in patients with chronic gastritis and peptic ulcer (Ayala
et al., 2011; Chihu et al., 2005; Garza-González et al., 2002;
Morales-Espinosa et al., 2007). In Latin America the prevalence of
clarithromycin resistance varies between populations and countries. In
Colombian patients, the frequency of clarithromycin resistance varies
from 15% to 60%. In 2012, it was reported 19.8% (29/172) of resistance
in patients with chronic gastritis (Figueroa et al., 2012). In 2009, of 46
isolates in patients 18 to 60 years old with dyspepsia found 15% of resis-
tance evaluated by disk-diffusion method (Henao et al., 2009); and
other study reported 60% (50/84) of clarithromycin resistance (Yepes
et al., 2008). It is likely that in the last two studies clarithromycin resis-
tance was underestimated due to the breakpoints deﬁned that classify
resistant strains. In strains isolates from Cuban patients with dyspepsia
found 10% (4/40) of resistance, by E-test method (Llanes et al., 2010).
On the other hand, in Indian patients with gastric pathologies 8% (2/
25) of resistance was found by disk-diffusion method and they used
similar breakpoints to those deﬁned in our study (Mishra et al., 2006).
The percentage of clarithromycin resistantH. pylori strainsmay be inﬂu-
enced by geographic region, method and procedures used for evalua-
tion, by the time to disease progression, age of patients and growingDistribution of H. pylori strains by genotype and clarithromycin resistance.
Genotype n (%)
Clarithromycin
n= 45
p value
Susceptible
n= 37
Resistant
n= 8
vacA s1m1/cagA+/babA2+ 12 (32.4) 3 (37.5) 0.376⁎
vacA s1m1/cagA+/babA2- 15 (40.6) 2 (25)
vacA s1m1/cagA-/babA2- 3 (8.1) 0
vacA s1m1/cagA-/babA2+ 0 1 (12.5)
vacA s2m2/cagA+/babA2+ 1 (2.7) 0
vacA s2m2/cagA-/babA2- 4 (10.8) 2 (25)
vacA s1m2/cagA+/babA2- 1 (2.7) 0
vacA s1m1/s1m2/cagA+/babA2+ 1 (2.7) 0
⁎ Fisher's exact test.
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not having or having had treatment with antibiotics for H. pylori eradi-
cation, however, it is not possible to discard information bias andmem-
ory bias. Thus, the percentage of clarithromycin resistant strains in the
Guerrero population can be explained by lack of adherence to treatment
regimen or previous use of clarithromycin or erythromycin indicated for
treatment of respiratory infections. The indiscriminate use of antibiotics
was a commonpractice inMexico. In Guerrero State,Mexico, until 2011,
antimicrobials were obtained without prescription and used for self-
medication. On the other hand, one ormore clones separable by culture,
can be in an isolate. We do not grow individual colonies, measure
clarithromycin resistance in a bacterial suspension of isolate and al-
though we did not get partial results, it is likely we may have
underestimated the prevalence of clarithromycin resistant strains be-
cause we studied a mixture of H. pylori colonies.
Although the disk-diffusionmethod is not the referencemethod, it is
still very useful for evaluating resistance to antibiotics. It is reported that
the results of thedisk-diffusionmethod are equivalent to those foundby
E-test (Mishra et al., 2006) or have a moderate correlation (Ogata et al.,
2015). Moreover, the disk-diffusion method is simple and easy to inter-
pret, widely used in medical bacteriology laboratories (Jorgensen and
Ferraro, 2009; Balouiri et al., 2015). The relationship between pheno-
typic clarithromycin resistance and the presence of mutations in the
23S rRNA gene was conﬁrmed in one of eight resistant strains by the
disk-diffusion method (A2143G mutation), and were found in three of
the eight strains mutations not previously reported, but they are not
commonly associated with clarithromycin resistance. Agudo et al.,
found that 19% (8/42) of phenotypically clarithromycin resistant strains
detected by E-test lacked point mutations in the 23S rRNA gene (Agudo
et al., 2010). It is likely that mutations found in our study are related to
clarithromycin resistance or that the resistance is given by another
mechanism, such as the presence of efﬂux pumps, production of meth-
ylases that modify the ribosome binding site (Hirata et al., 2010; Bina
et al., 2000), or the presence of plasmids containing antibiotic resistance
genes. The Resistance-Nodulation-cell Division (RND family) is respon-
sible formacrolide intrinsic resistance in several Gram negative bacteria
and it has been recently proposed also forH. pylori. It has been observed
in detail that 4 RND gene clusters (HP0605-HP0607, HP0971-HP-0969,
HP1327-HP1329, HP1489-HP1487) in the efﬂux pump system play a
role in promoting multidrug resistance in H. pylori (Zhang et al., 2010;
De Francesco et al., 2011). Is possible that in susceptible strains,
clarithromycin binds preferentially to the ribosomal subunits rather
than the efﬂux pumps (De Francesco et al., 2011). Other resistance
mechanisms acquired by macrolides, like clarithromycin, have modiﬁ-
cations to the ribosome binding site which can consist of: methylation
of an adenine residue or changes in base sequence of 23S rRNA or alter-
ations of the L4 ribosomal protein. The monomethylation causes cross-
resistance to allmacrolides.Mutation of the L4 protein alters the tertiary
structure of 23S rRNA in domain V and indirectly inﬂuences the
macrolide afﬁnity. Mutations are selected during treatment and can be
observedwhen amacrolide is used in amonotherapy for Staphylococcus
aureus infection or H. pylori (Cobos-Trigueros et al., 2009). On the other
hand, previous reports have shown that the presence of the A2143G
point mutation, rather than the A2142G or A2142Cmutation, markedly
reducesH. pylori eradication rate (De Francesco et al., 2006). It has been
suggested that a mutational event detected in vitro does not precisely
explain in vivo results (De Francesco et al., 2009).
In agreement with previous studies (Martínez-Carrillo et al.,
2010; Román-Román et al., 2013, Martínez-Carrillo et al., 2014) we
found that the vacA s1m1 genotype is the most common, 82.2%
(37/45), in Mexican patients from Guerrero State with chronic gas-
tritis and H. pylori infection, similar to that found in other geograph-
ical areas of the country (Ayala et al., 2011;. Garza-González et al.,
2004; González-Valencia et al., 2000; Paniagua et al., 2009). The
vacA s1m1mosaicismwas detectedmore frequently in cagA+ strains
(73.3%) and s2m2 allelic combination was more common in cagA-strains, 85.7% (6/7), similar to that observed in another study in
our region (Martínez-Carrillo et al., 2014). This distribution of geno-
type differs from that observed in Spain and other countries (Agudo
et al., 2010). On the other hand, we found that one patient harbored
N1 vacA genotype of H. pylori [vacA s1m1/s1m2/cagA+/babA2+, 2.2%
(1/45)]. This ﬁnding is in agreement with that reported by
Gonzalez-Valencia et al. and Roman-Román et al., who found that
gastric infection with more than one vacA genotype of H. pylori in
the same biopsy is more frequent in Mexico than in other countries
(González-Valencia et al., 2000; Román-Román et al., 2013).
It is proposed that the genotype of the strain can affect the suc-
cess of eradication therapy for H. pylori (Sugimoto and Yamaoka,
2009). In this study no signiﬁcant differences in clarithromycin resis-
tance with vacA genotype and cagA status of H. pylori (p N 0.05;
Table 4); while 62.2% (28/45) of the vacA s1m1/cagA+ strains were
clarithromycin susceptible and 11.1% (5/45) were phenotypically re-
sistant and 4.4% (2/45) of patients had resistant isolations with vacA
s2m2/cagA-/babA2- genotypes. Our results indicate a difference in
sensitivity to therapy between theH. pylori genotypes. SomeH. pylori
strains could be intrinsically more susceptible to antibiotic treat-
ment than others. Previous reports have shown that the vacA s2m2/
cagA- strains seems to be more resistant to therapy than vacA
s1m1/cagA+ and vacA s1m2/cagA+ strains. vacA s1/cagA+ strains
may proliferate faster than vacA s2/cagA- strains, and would there-
fore be more susceptible to antibiotic activity that interferes with
the metabolism of a dividing cell. We agree with van Doorn et al.,
who proposed that antibiotics can reach higher concentrations in in-
ﬂamed mucosa. Thus, vacA s2/cagA+ strains, that produce less severe
inﬂammation, would be less accessible to antibiotics and therefore
more difﬁcult to eradicate (Van Doorn et al., 2000).
It is proposed that virulent strains (vacA s1m1/cagA+) can be
more easily removed with eradication therapy for H. pylori, than
less virulent strains (vacA s2m2/cagA-) (Agudo et al., 2010;
Sugimoto and Yamaoka, 2009); which can be applied to 62.2% of
clarithromycin susceptible strains identiﬁed in this research. We
found that the highest proportion of resistant strains, 62.5% (5/8)
were vacA s1m1/cagA+ genotype, as reported by other authors
(Ayala et al., 2011; Elviss et al., 2004; Ghotaslou et al., 2013) and
50% of them had vacA s1m1/cagA+/babA2+ combination. To our
knowledge, there are no published studies which included babA2
in genotype of resistant strains. It is likely that BabA2 is favoring per-
sistence of H. pylori, to ensure adherence to epithelial cells. The vacA
s1m1/cagA+ and vacA s1m1/cagA+/babA2+ genotypes are associated
with more severe gastric diseases due to the fact that strains with
those genotypes induce severe inﬂammation with increased pro-
duction of IL-1β and TNF-α, potent inhibitors of secretion of hydro-
chloric acid and consequently inducing increased gastric pH;
conditions that may favor the action of clarithromycin and the per-
sistence of the bacterium. It is likely that infected patients with
clarithromycin resistant strains vacA s1m1/cagA+ and vacA s1m1/
cagA+/babA2+ are at increased risk of progression to more severe
conditions by failure in H. pylori eradication. Thus, in this popula-
tion, 62.5% (5/8) of infected patients with vacA s1m1/cagA+
clarithromycin resistant strains are at increased risk of severe dis-
ease than infected patients with vacA s1m1/cagA- clarithromycin re-
sistant (12.5% [1/8]) or vacA s2m2/cagA- (25% [2/8]), however, all
must be closely monitored.
The results of this research suggest that current therapy regi-
mens may be particularly suited to eradicate the more virulent
(vacA s1m1/cagA+) H. pylori strains but it will be necessary to deter-
mine the genotypes of strains that infect patients who do not re-
spond the therapy and clarithromycin resistance should be
monitored in this geographical area. The Maastricht Consensus sug-
gest that the triple therapy should be abandoned when
clarithromycin resistance reaches N20% in the region. More studies
are needed in other regions of Guerrero State.
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In patients from southern Mexico with chronic gastritis, the preva-
lence of clarithromycin resistance strains is within internationally ac-
cepted ranges (17.8%) and allows for continued use of triple therapy
for H. pylori eradication. However, it is necessary to monitor the evolu-
tion of clarithromycin resistance in this area. The largest proportion of
resistant H. pylori strains not harboring the A2142G, A2142C and
A2143G mutations in the 23S rRNA gene (87.5%), thus the existence of
other mechanisms of clarithromycin resistance in H. pylori is likely.
The vacA s1m1/cagA+ genotype was the most prevalent and among
clarithromycin-resistant strains, this was the predominant genotype.
There was no signiﬁcant difference found in clarithromycin resistance
with H. pylori genotypes. It is likely that infected patients with
clarithromycin resistant strains vacA s1m1/cagA+ and vacA s1m1/
cagA+/babA2+ are at increased risk of progression to more severe con-
ditions by failure in H. pylori eradication.
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